Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE) NTLA-2002 is Intellia’s second in vivo candidate ...

Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass ...

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...

Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET To join the webcast, please visit this link, or the Events and Presentations page of ...